Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,283 | -3,178 | -2,058 | -1,112 | -1,685 |
| Depreciation Amortization | 7 | 67 | 63 | 59 | 42 |
| Accounts payable and accrued liabilities | -48 | 149 | 262 | 58 | 12 |
| Other Working Capital | 217 | 41 | 62 | -98 | -151 |
| Other Operating Activity | 290 | -631 | -1,219 | -1,285 | 634 |
| Operating Cash Flow | $-816 | $-3,553 | $-2,890 | $-2,378 | $-1,149 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -11 | -11 | -11 | -11 |
| Investing Cash Flow | $N/A | $-11 | $-11 | $-11 | $-11 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | 1,132 | 408 | 0 | 0 | 0 |
| Financing Cash Flow | $1,132 | $408 | $N/A | $N/A | $N/A |
| Beginning Cash Position | 102 | 3,221 | 3,221 | 3,221 | 3,221 |
| End Cash Position | 418 | 65 | 320 | 832 | 2,062 |
| Net Cash Flow | $316 | $-3,156 | $-2,901 | $-2,390 | $-1,160 |
| Free Cash Flow | |||||
| Operating Cash Flow | -816 | -3,553 | -2,890 | -2,378 | -1,149 |
| Capital Expenditure | N/A | -11 | -11 | -11 | -11 |
| Free Cash Flow | -816 | -3,564 | -2,901 | -2,390 | -1,160 |